Trial Outcomes & Findings for Outcomes for One-stage and Two-stage Brachial Basilic Arteriovenous Fistulas (NCT NCT04376567)
NCT ID: NCT04376567
Last Updated: 2025-09-11
Results Overview
Functional clinical patency means the number of participants who were able to use their brachial basilic arteriovenous fistula (BBAVF) successfully for dialysis within 6 months of surgical creation. It refers to using two dialysis needles in at least 75% of dialysis sessions over four weeks without need for additional procedure or surgery, as determined by their providers.
TERMINATED
NA
2 participants
6 months
2025-09-11
Participant Flow
Participant milestones
| Measure |
One Stage Approach
To create a brachial-basilic arteriovenous fistula (BBAVF) using a one-stage approach. The arteriovenous anastomosis is performed and the basilic vein is transposed during the same procedure.
One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
|
Two Stage Approach
To create a BBAVF using a two-stage approach, the arteriovenous anastomosis is performed during the first procedure. The superficialization or transposition of the fistula is then performed 6 to 8 weeks later, after the fistula has matured.
One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
|
|---|---|---|
|
Overall Study
STARTED
|
1
|
1
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
1
|
1
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Outcomes for One-stage and Two-stage Brachial Basilic Arteriovenous Fistulas
Baseline characteristics by cohort
| Measure |
One Stage Approach
n=1 Participants
To create a brachial-basilic arteriovenous fistula (BBAVF) using a one-stage approach. The arteriovenous anastomosis is performed and the basilic vein is transposed during the same procedure.
One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
|
Two Stage Approach
n=1 Participants
To create a BBAVF using a two-stage approach, the arteriovenous anastomosis is performed during the first procedure. The superficialization or transposition of the fistula is then performed 6 to 8 weeks later, after the fistula has matured.
One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
|
Total
n=2 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Dialysis
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: 6 monthsFunctional clinical patency means the number of participants who were able to use their brachial basilic arteriovenous fistula (BBAVF) successfully for dialysis within 6 months of surgical creation. It refers to using two dialysis needles in at least 75% of dialysis sessions over four weeks without need for additional procedure or surgery, as determined by their providers.
Outcome measures
| Measure |
One Stage Approach
n=1 Participants
To create a brachial-basilic arteriovenous fistula (BBAVF) using a one-stage approach. The arteriovenous anastomosis is performed and the basilic vein is transposed during the same procedure.
One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
|
Two Stage Approach
n=1 Participants
To create a BBAVF using a two-stage approach, the arteriovenous anastomosis is performed during the first procedure. The superficialization or transposition of the fistula is then performed 6 to 8 weeks later, after the fistula has matured.
One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
|
|---|---|---|
|
Number of Participants Who Had Successful Use of Arteriovenous Fistula for Dialysis
|
1 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: 6 monthsNumber of participants with dialysis catheter related complications, including infection, procedure to exchange catheter due to malfunction. outcomes of Primary Clinical Functional Patency or CVC-related bacteremia or death
Outcome measures
| Measure |
One Stage Approach
n=1 Participants
To create a brachial-basilic arteriovenous fistula (BBAVF) using a one-stage approach. The arteriovenous anastomosis is performed and the basilic vein is transposed during the same procedure.
One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
|
Two Stage Approach
n=1 Participants
To create a BBAVF using a two-stage approach, the arteriovenous anastomosis is performed during the first procedure. The superficialization or transposition of the fistula is then performed 6 to 8 weeks later, after the fistula has matured.
One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
|
|---|---|---|
|
Number of Participants Who Had Catheter Related Complications
|
1 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: 6 monthsNumber of participants who had \> 3 months of catheter dependency after arteriovenous fistula creation
Outcome measures
| Measure |
One Stage Approach
n=1 Participants
To create a brachial-basilic arteriovenous fistula (BBAVF) using a one-stage approach. The arteriovenous anastomosis is performed and the basilic vein is transposed during the same procedure.
One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
|
Two Stage Approach
n=1 Participants
To create a BBAVF using a two-stage approach, the arteriovenous anastomosis is performed during the first procedure. The superficialization or transposition of the fistula is then performed 6 to 8 weeks later, after the fistula has matured.
One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
|
|---|---|---|
|
Number of Participants Who Had > 3 Months of Catheter Dependency After Arteriovenous Creation
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: 6-monthPopulation: Participate did not complete PROMIS questionnaire.
Average quality of life scores assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) for physical function, fatigue, sleep disturbance, and ability to participate in social roles and activities. Data are presented as T-score, which are standardized scores with a mean of 50 and a standard deviation for the reference population (typically the US general population). A T-score of 50 represents the population average. A higher T-score indicates more of the concept being measured and lower T-score indicate less.
Outcome measures
| Measure |
One Stage Approach
n=1 Participants
To create a brachial-basilic arteriovenous fistula (BBAVF) using a one-stage approach. The arteriovenous anastomosis is performed and the basilic vein is transposed during the same procedure.
One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
|
Two Stage Approach
To create a BBAVF using a two-stage approach, the arteriovenous anastomosis is performed during the first procedure. The superficialization or transposition of the fistula is then performed 6 to 8 weeks later, after the fistula has matured.
One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
|
|---|---|---|
|
Patient-Reported Outcomes Measurement Information System Scores Over 6 Months
Physical function (T-score)
|
37.5 score on a scale
Standard Deviation 33.2
|
—
|
|
Patient-Reported Outcomes Measurement Information System Scores Over 6 Months
Fatigue (T-score)
|
52.3 score on a scale
Standard Deviation 61.6
|
—
|
|
Patient-Reported Outcomes Measurement Information System Scores Over 6 Months
Sleep disturbance (T-score)
|
53.6 score on a scale
Standard Deviation 39.6
|
—
|
|
Patient-Reported Outcomes Measurement Information System Scores Over 6 Months
Ability to participate in social roles and activities (T-score)
|
44.7 score on a scale
Standard Deviation 23.7
|
—
|
Adverse Events
One Stage Approach
Two Stage Approach
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place